Jim Cashman is an veteran of the software industry for over 45 years, and serves as an advisor to numerous high tech companies. He most recently served for 20 years in the CEO and Executive Chairman roles of ANSYS, Inc. which grew from $50 million to over $1 billion in revenues over his tenure. During that span, ANSYS was one of the top 5 public technology companies in terms of total shareholder returns, while joining the S&P500 and NASDAQ-100. He has evangelized Simulation Driven Product Development which enables organizations to develop virtual prototypes, resulting in reduced testing, faster time-to-market, and better quality products. As such, he has been featured in many publications, as well as on CNBC, CNN, FBN, Bloomberg and other on-air networks.
Mr. Broshy is an accomplished veteran board director and private equity operating executive with more than 35 years of experience working broadly across healthcare. Mr. Broshy also served for over a decade as chief executive officer and chairman of inVentiv Health (Nasdaq: VTIV, now part of Syneos Health), and under his leadership the company transformed into the leading global provider of clinical and commercialization services. Earlier in his career, he spent 15 years at The Boston Consulting Group (BCG), where he was a managing director and partner responsible for the firm’s healthcare practice across the Americas. Mr. Broshy currently serves on the boards of Theravance Biopharma (Nasdaq: TBPH), a respiratory-focused biotech company, and Thirty Madison, a digital healthcare company. He is also a member of the Corporation of the Massachusetts Institute of Technology.
Cynthia Collins served as Chief Executive Officer of Editas Medicine, Inc. (Nasdaq:EDIT) from March 2019 to February 2021.. Previously, Ms. Collins served as Chief Executive Officer of Human Longevity Inc. and Chief Executive Officer/General Manager of General Electric’s Healthcare Cell Therapy and Lab Businesses and GE’s Clarient Diagnostics. Prior to GE, Ms. Collins served as CEO of GenVec (NASDAQ:GNVC), a vaccine and gene therapy company and before that, she served as Group Vice President, Cellular Analysis Business of Beckman Coulter with responsibility for its Hematology, Flow Cytometry, and Hemostasis businesses.
Ms. Collins serves as a member of the board of directors of Poseida Therapeutics, a cell and gene therapy company, since August 2021.
Ms. Collins received her BS degree in Microbiology from the University of Illinois, Urbana and her MBA from The University of Chicago Booth School of Business. She is currently a member of the boards of Poseida Therapeutics (PSTX) and DermTech, Inc. (DMTK).
Ms. Rosemary Crane has over 37 years of experience in the healthcare industry, with a strong focus in commercialization and business operations. She has more than 25 years of therapeutic
and consumer drug launch experience.
Ms. Crane served as President and Chief Executive Officer of MELA Sciences and was a partner at Appletree Partners. She also served as President and Chief Executive Officer of Epocrates, where she led a very successful IPO. She served in various senior executive positions at Johnson & Johnson, including as Group Chairman, OTC & Nutritional Group, as Group Chairman, Consumer, Specialty Pharmaceuticals and Nutritionals. Prior to that, Ms. Crane managed a $7 billion business as President US Primary Care at Bristol Myers Squibb,
Ms. Crane currently serves on the Board of Directors for Tarsus Pharmaceuticals (Nasdaq: TARS), Catalent Pharma Solutions (NYSE: CTLT) and Teva Pharmaceuticals (NYSE: TEVA). She is also the Vice Chairman of the Foundation Board at State University of New York at Oswego.
Dr. Feehery has served as Chief Executive Officer of Certara since June 2019. His joined Certara from DuPont, where he served since 2013 as President of Industrial Biosciences, a global biotechnology business that experienced significant growth and profitability under his leadership. He joined DuPont in 2002 and served in a number of operating roles in high-growth businesses, and he also has previous experience in venture capital and as a consultant for the Boston Consulting Group.
Dr. Feehery also serves as a board member for West Pharmaceutical Services (NYSE: WST), a manufacturer of packaging components and delivery systems for pharmaceutical, biotech and medical device companies.
Dr. Feehery holds both a Ph.D. in chemical engineering and an MBA from MIT, was a Churchill Scholar at Cambridge University and received his BSE in chemical engineering from the University of Pennsylvania. His doctorate, awarded while he was the recipient of a National Science Foundation Fellowship, involved developing software and mathematical methods for modeling dynamic systems.
Nancy Killefer served as a Senior Partner at McKinsey & Company, an international management consulting firm, from 1992 until her retirement in August 2013. She joined McKinsey in 1979 and held a number of leadership roles, including serving as a member of the firm’s governing board. Ms. Killefer also served as Assistant Secretary for Management, Chief Financial Officer, and Chief Operating Officer of the U.S. Department of the Treasury from 1997 to 2000 and as a member of the IRS Oversight Board from 2000 to 2005, including as Chair of the IRS Oversight Board from 2002 to 2004.
Ms. Killefer also serves on the boards of directors of Meta Platforms, Inc. (f/k/a Facebook, Inc.) since March 2020, Cardinal Health, Inc., a healthcare services company, since September 2015 and Natura & Company, a global personal care cosmetics group, since January 2020.
Ms. Killefer holds a B.A. in economics from Vassar College and an M.S. in management from the Massachusetts Institute of Technology.
Eric Liu is a Partner, Head of North American Private Equity, and Global Co-Head of Healthcare at EQT. EQT is an alternative asset management firm headquartered in Sweden, with over €77 billion in assets under management. He joined in 2014 to establish and build out the firm’s large-cap buyout operations in the U.S. The firm is currently investing EQT IX, a €15.6 billion private equity fund closed in 2021. Eric led the firm’s investments and serves on the Board of Directors of Certara, Parexel, and Waystar, and was previously responsible for Aldevron and Press Ganey.
Prior to joining EQT, Eric spent ten years at Warburg Pincus where he was responsible for private equity investments in the healthcare sector, including Bausch & Lomb, Tornier, ev3, and DexCom. Earlier in his career, he worked in private equity at The Blackstone Group and in early-stage venture capital at Draper Fisher Jurvetson.
Eric has a B.A. in Applied Mathematics, phi beta kappa, from Harvard University and an MBA from the Stanford Graduate School of Business, where he was an Arjay Miller Scholar.
Mr. McLean is the Senior Partner, Healthcare Group at Arsenal Capital Partners, a New York City-based private equity firm. Previously, Mr. McLean was a founding Partner of Merrill Lynch Capital Partners, Inc. McLean serves on a number of corporate boards including WIRB Copernicus Group, Inc., Accumen, Inc., CellCarta, and Best Value Healthcare LLC. He is the Chairman and a founder of the International Biomedical Research Alliance.
McLean holds a BS in Economics, summa cum laude and an MBA with Distinction, both earned from the Wharton School of the University of Pennsylvania.
Mr. Slaine is the Chairman of PRO Unlimited, which provides workforce management software and services and Executive Chairman of MLM2, a business software and data company. He has led investments through the Slaine Family Office since January 2016. Prior to that, Mr. Slaine was the Executive Chairman of Interactive Data Corporation, the financial markets data and analytics company, from 2010 to December 2015, when it was acquired by The Intercontinental Exchange, the financial and commodity markets company.
Mr. Slaine is Chairman of the board of directors of Cast & Crew Entertainment Services, an entertainment payroll provider, and a board member of Reorg Research, Inc., a provider of news, commentary and analysis related to the debt markets.
Mr. Slaine holds an A.B., magna cum laude, from Amherst College and an MBA from Harvard University.
Mr. Walsh has served as Executive Vice President and Chief Financial Officer of Organon & Co., a global pharmaceutical business since June 2020. Prior to Organon, he served as Executive Vice President and Chief Financial Officer of Allergan, a publicly traded, global biopharmaceutical company, from 2018 until the sale of the company to Abbvie in 2020. From 2008 to 2018, Mr. Walsh served as Chief Financial Officer of Catalent, a global provider of delivery technologies, development, and manufacturing solutions to the life sciences industry. Before Catalent, from 2006 to 2008, he was President, Chief Financial Officer and Acting Chief Executive Officer at Escala Group, Inc.
Mr. Walsh earned his Bachelor of Science degree in chemical engineering from Cornell University, and an M.B.A. from Cornell University, SC Johnson School of Management. Mr. Walsh is a CFA® charterholder.
Mr. Waxman serves as a Managing Director at EQT, where he has worked since August 2015. He previously served as a board observer to our board of directors from August 2017 to August 2020. Mr. Waxman served as a non-employee executive officer for the Company and certain of our subsidiaries from June 2017 to October 2020.
Mr. Waxman has a B.A., phi beta kappa, from Harvard University.